Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04264260 | Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | completed | Phase 2 | 42 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03037437 | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | completed | Phase 2 | 64 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2025 |
| clinicaltrials |
| NCT03638141 | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | completed | Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT01356628 | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | completed | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT04611165 | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC(Nextrah) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT05750030 | FMT in IT-refractory HCC - FAB-HCC Pilot Study | completed | Phase 2 | 12 | Medical University of ViennaOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | completed | Phase 2 | 35 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04000737 | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 62 | Yiviva Inc.INDUSTRY | 4 | Apr 13, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT03009461 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | completed | Phase 2 | 64 | Peking UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 39 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04954794 | TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | completed | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT04011033 | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | completed | Phase 2 | 60 | Beijing YouAn HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | completed | Phase 2 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT04170556 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)(GOING) | completed | Phase 1 / Phase 2 | 69 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 52 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT03510871 | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 43 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04518852 | TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | completed | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06232759 | TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 56 | Guangxi Medical UniversityOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT04172571 | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 31 | AkesoINDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04842565 | cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | completed | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT05040438 | Natural Killer (NK) Cell Therapy in Locally Advanced HCC | completed | Phase 2 | 17 | Vaxcell Bio, Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04728321 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 32 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials